Assessing the Clinical Influence of Chronic Total Occlusions (CTOs) Revascularization and the Impact of Vascularization Completeness on Patients with Left Ventricular (LV) Systolic Dysfunction
Table 1
Baseline and angiographical features between SCR and OMT patients.
Variable
SCR (n = 135)
OMT (n = 126)
value
Male gender
105 (77.8)
95 (75.4)
0.663
Age
64.75 ± 9.03
68.41 ± 9.57
0.020
≧75 years of age
22 (16.3)
38 (30.2)
0.008
Hypertension
91 (67.4)
80 (63.5)
0.518
BMI (kg/m2)
24.22 (22.27, 26.15)
23.66 (20.89, 25.65)
0.185
Previous smoker
98 (72.6)
84 (87.9)
0.346
Diabetes mellitus
51 (37.8)
37 (42.5)
0.190
Previous MI
73 (54.1)
40 (31.7)
<0.001
Previous PCI
27 (20.0)
8 (6.3)
0.002
Previous CABG
3 (2.2)
0 (0)
0.270
eGFR (ml/min)
69.87 ± 24.60
70.00 ± 25.30
0.966
ICD
4 (3.0)
4 (3.2)
1.000
CPOD
14 (10.4)
19 (15.1)
0.269
Previous stroke
21 (15.6)
16 (12.7)
0.595
Peripheral artery disease
2 (1.5)
0 (0)
0.499
Baseline LVEF (%)
30.92 ± 6.92
31.38 ± 6.65
0.594
Triglyceride (mmol/l and mg/dL)
1.29 (0.97, 1.78)
1.28 (0.94, 1.99)
0.687
Total cholesterol (mmol/l and mg/dL)
4.08 (3.32, 4.95)
3.96 (3.35, 4.93)
0.871
LDL-C (mmol/l and mg/dL)
2.46 (2.07, 2.95)
2.34 (1.95, 3.24)
0.764
HDL-C (mmol/l and mg/dL)
0.98 (0.86, 1.18)
1.04 (0.86, 1.27)
0.215
Medications
Aspirin
131 (97.0)
111 (88.1)
0.007
Clopidogrel/ticagrelor
135 (100)
121 (96.0)
0.059
Statin
130 (96.3)
123 (97.6)
0.795
Beta blocker
131 (97.0)
118 (93.7)
0.243
ACEI or ARB or ARNI
121 (89.6)
120 (95.2)
0.106
Anticoagulatant therapy
84 (62.2)
82 (65.1)
0.700
Angina (CCS class)
No angina
0
0
I
0
1 (0.8)
II
35 (22.2)
23 (18.3)
III
72 (53.3)
65 (51.6)
IV
28 (20.7)
37 (29.4)
Dyspnea (NYHA functional class)
I
2 (1.5)
1 (0.8)
II
46 (34.1)
31 (24.6)
III
54 (40.0)
55 (43.7)
IV
33 (24.4)
39 (30.9)
Target CTO artery
LAD
51 (37.8)
46 (36.5)
RCA
54 (40.0)
51 (40.5)
LXC
30 (22.2)
29 (23.0)
In stent CTO
6 (4.4)
10 (7.9)
0.305
J-CTO scoring
2.54 ± 0.94
2.72 ± 0.76
0.042
J-channel scoring
1.88 ± 1.17
2.60 ± 0.86
<0.001
SYNTAX score
29.32 ± 8.69
30.34 ± 7.51
0.477
Number of narrowed coronary arteries
1
14 (10.4)
10 (7.9)
2
34 (25.2)
29 (23.0)
3
87 (64.4)
87 (69.0)
LM disease
13 (9.6)
20 (15.9)
0.14
Note. Data are expressed as average ± SD, n (%), n/N (%), or mid-value (interquartile range). Abbreviations: eGFR, estimated glomerular filtration rate; BMI, body mass index; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; ICD, implantable cardioverter defibrillator; PCI, percutaneous coronary intervention; DAPT, dual anti-platelet therapy; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CKD, chronic kidney disease; NYHA, New York heart association; CCS, Canadian cardiovascular society; ARNI, Angiotensin receptor enkephalinase inhibitor; J-CTO, Japanese multicenter registry; LAD, left anterior descending; LCX, left circumflflex; RCA, right coronary artery; LM disease, left main disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; SCR, successful CTO revascularization; OMT, optimal medical therapy; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
